<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234065</url>
  </required_header>
  <id_info>
    <org_study_id>C02100-002</org_study_id>
    <secondary_id>JapicCTI-050034</secondary_id>
    <secondary_id>UMIN-CTR-C000000129</secondary_id>
    <nct_id>NCT00234065</nct_id>
  </id_info>
  <brief_title>Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)</brief_title>
  <official_title>Post-marketing Study of Cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison With Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy of cilostazol in preventing
      recurrence of cerebral infarction and the safety of long-term administration of the drug (100
      mg, twice daily) in patients with cerebral infarction (excluding cardiogenic cerebral
      embolism) in a multi-center, double-blind, parallel-group comparison with aspirin (81 mg,
      once daily).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Patients With First Occurence of Stroke</measure>
    <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])</time_frame>
    <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With First Recurrence of Cerebral Infarction</measure>
    <time_frame>From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease</measure>
    <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
    <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths From Any Cause</measure>
    <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
    <description>Number of deaths from any cause. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events</measure>
    <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
    <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients' treatment assignment, adjudicated all trial endpoints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2800</enrollment>
  <condition>Cerebral Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aspirin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with stable medical conditions for 182 days (26 weeks) after occurrence of
             cerebral infarction

          2. Patients in whom the infarct-related foci was detected by X-ray CT scan or MRI

          3. Patients aged 20 to 80 years (inclusive) at time of consent

          4. Patients with none of the following cardiac diseases that may be associated with
             cardiogenic cerebral embolism: mitral stenosis, prosthetic heart valve, endocarditis,
             myocardial infarction within 6 weeks after occurrence, ventricular aneurysm,
             endocardial thrombosis, mitral valve prolapse (patients less than 45 years of age in
             whom no other cause was identified), atrial fibrillation, sick sinus syndrome,
             idiopathic cardiomyopathy, and patent foramen ovale

          5. Patients without asymptomatic cerebral infarction

          6. Patients who have neither undergone nor are scheduled to undergo percutaneous
             transluminal angioplasty or revascularization for the treatment of cerebral infarction

          7. Patients without severe disturbances/impairments following occurrence of cerebral

        Exclusion Criteria:

          1. Patients with hemorrhage or bleeding tendency (hemophilia, capillary fragility,
             intracranial hemorrhage, hemorrhage in the digestive tract, hemorrhage in the urinary
             tract, hemoptysis, and hemorrhage in the vitreous body)

          2. Pregnant, possibly pregnant, or nursing women

          3. Patients with ischemic heart failure

          4. Patients with peptic ulcer

          5. Patients with severer blood disorders

          6. Patients with severe hepatic or renal

          7. Patients with malignant neoplasm or patients who have received any therapy for
             malignant neoplasm within 5 years prior to entering the study

          8. Patients with a history of hypersensitivity to salicylic acid formulations or
             ingredients of cilostazol tablets

          9. Patients with aspirin asthma (asthma attacks induced by nonsteroidal antiinflammatory
             analgesic agents) or a history of aspirin asthma

         10. Patients who are being treated with ticlopidine hydrochloride

         11. Patients who are participating in another study for an investigational drug

         12. Patients who are otherwise judged inappropriate for inclusion in the study by the
             investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masahiko Abe</last_name>
    <role>Study Director</role>
    <affiliation>Division of New Product Evaluation and Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Otsuka Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, Tanahashi N, Yamamoto H, Genka C, Kitagawa Y, Kusuoka H, Nishimaru K, Tsushima M, Koretsune Y, Sawada T, Hamada C; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 Oct;9(10):959-68. doi: 10.1016/S1474-4422(10)70198-8. Epub 2010 Sep 15.</citation>
    <PMID>20833591</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2005</study_first_posted>
  <results_first_submitted>April 19, 2011</results_first_submitted>
  <results_first_submitted_qc>April 19, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2011</results_first_posted>
  <last_update_submitted>June 9, 2011</last_update_submitted>
  <last_update_submitted_qc>June 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Katsuhisa Saito</name_title>
    <organization>OPCJ</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with non-cardioembolic ischemic stroke have been recruited at 278 study sites in Japan between December, 2003, and October, 2006.</recruitment_details>
      <pre_assignment_details>No screening period</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cilostazol</title>
          <description>cilostazol, oral tablet, 100 mg cilostazol</description>
        </group>
        <group group_id="P2">
          <title>Aspirin</title>
          <description>Aspirin, oral tablet, 81 mg aspirin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1356"/>
                <participants group_id="P2" count="1360"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="881"/>
                <participants group_id="P2" count="1004"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="475"/>
                <participants group_id="P2" count="356"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="268"/>
                <participants group_id="P2" count="166"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Classified</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cilostazol</title>
          <description>cilostazol, oral tablet, 100 mg cilostazol</description>
        </group>
        <group group_id="B2">
          <title>Aspirin</title>
          <description>Aspirin, oral tablet, 81 mg aspirin</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1337"/>
            <count group_id="B2" value="1335"/>
            <count group_id="B3" value="2672"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="681"/>
                    <measurement group_id="B2" value="685"/>
                    <measurement group_id="B3" value="1366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="656"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="1306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.5" spread="9.2"/>
                    <measurement group_id="B2" value="63.4" spread="9.0"/>
                    <measurement group_id="B3" value="63.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="378"/>
                    <measurement group_id="B2" value="378"/>
                    <measurement group_id="B3" value="756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="959"/>
                    <measurement group_id="B2" value="957"/>
                    <measurement group_id="B3" value="1916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1337"/>
                    <measurement group_id="B2" value="1335"/>
                    <measurement group_id="B3" value="2672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Patients With First Occurence of Stroke</title>
        <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
        <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [Standard Deviation 16, range 1-59 months])</time_frame>
        <population>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol, oral tablet, 100 mg cilostazol</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Aspirin, oral tablet, 81 mg aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients With First Occurence of Stroke</title>
          <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage or subarachnoid haemorrhage. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
          <population>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1337"/>
                <count group_id="O2" value="1335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis 1 for Number of Patients With First Occurrence of Stroke</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the upper 95% CI limit for the HR of cilostazol to aspirin was 1.33 (4/3) or lower , cilostazol would be non-inferior to aspirin.</non_inferiority_desc>
            <p_value>0.0357</p_value>
            <p_value_desc>The log-rank test was used to verify the superiority of CLZ to ASA only if non-inferiority was verified. The adjusted significance level for the superiority test of the endpoint was set at 0.0471 (two-tailed) according to the O’Brien-Fleming method.</p_value_desc>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.743</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.564</ci_lower_limit>
            <ci_upper_limit>0.981</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With First Recurrence of Cerebral Infarction</title>
        <time_frame>From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol, oral tablet, 100 mg cilostazol</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Aspirin, oral tablet, 81 mg aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Recurrence of Cerebral Infarction</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1337"/>
                <count group_id="O2" value="1335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4189</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio, log</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.645</ci_lower_limit>
            <ci_upper_limit>1.200</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease</title>
        <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
        <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
        <population>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol, oral tablet, 100 mg cilostazol</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Aspirin, oral tablet, 81 mg aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Occurrence of Ischaemic Cerebrovascular Disease</title>
          <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction or the first occurrence of transient ischaemic attack. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
          <population>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1337"/>
                <count group_id="O2" value="1335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4582</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.898</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.675</ci_lower_limit>
            <ci_upper_limit>1.194</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths From Any Cause</title>
        <description>Number of deaths from any cause. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
        <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol, oral tablet, 100 mg cilostazol</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Aspirin, oral tablet, 81 mg aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths From Any Cause</title>
          <description>Number of deaths from any cause. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1337"/>
                <count group_id="O2" value="1335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8600</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.497</ci_lower_limit>
            <ci_upper_limit>2.313</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events</title>
        <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
        <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol, oral tablet, 100 mg cilostazol</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Aspirin, oral tablet, 81 mg aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Occurrence of a Composite Endpoint of Stroke, Haemorrhagic Events, or Cardiovascular Events</title>
          <description>The endpoint in this measure is a composite endpoint of the first recurrence of cerebral infarction, or occurrence of cerebral haemorrhage, subarachnoid haemorrhage, transient ischaemic attack, angina pectris, myocardial infarction, heart failure, or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1337"/>
                <count group_id="O2" value="1335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0437</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.799</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.643</ci_lower_limit>
            <ci_upper_limit>0.994</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With First Occurrence of Haemorrhagic Event</title>
        <description>The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
        <time_frame>From start of treatment to end of follow-up period ( follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>cilostazol, oral tablet, 100 mg cilostazol</description>
          </group>
          <group group_id="O2">
            <title>Aspirin</title>
            <description>Aspirin, oral tablet, 81 mg aspirin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With First Occurrence of Haemorrhagic Event</title>
          <description>The endpoint in this measure is a composite endpoint of the first occurrence of cerebral haemorrhage, subarachnoid haemorrhage or haemorrhage requiring hospital admission. The evaluation committee, whose members were unaware of patients’ treatment assignment, adjudicated all trial endpoints.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1337"/>
                <count group_id="O2" value="1335"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analyses were done using the full analysis set (FAS) of patients, as predetermined in the protocol. The full analysis set excluded patients who failed to satisfy inclusion criteria and those who violated exclusion criteria.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.458</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.296</ci_lower_limit>
            <ci_upper_limit>0.711</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment to end of follow-up period (mean follow-up periods : 29 months [STANDARD DEVIATION 16, range 1-59 months])</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cilostazol</title>
          <description>cilostazol, oral tablet, 100 mg cilostazol</description>
        </group>
        <group group_id="E2">
          <title>Aspirin</title>
          <description>Aspirin, oral tablet, 81 mg aspirin</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Ver.12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="372" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="433" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Intracardiac thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Intestinal malrotation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Vertigo labyrinthine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diabetic retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pterygium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Entropion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ulcerative keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Tolosa-Hunt syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Reflux oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Large intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diverticulitis intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastroduodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gingival hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Large intestinal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Disuse syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Extradural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Spinal ligament ossification</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Axillary mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Large intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Gastric adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Spinal cord neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Salivary gland adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Presenile dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Vertebral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Reversible ischaemic neurological deficit</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Putamen haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Vertebral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis rapidly progressive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Ver.12.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1267" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="1260" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="156" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="164" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="155" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="546" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="590" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="312" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="1335"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="105" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="120" subjects_at_risk="1337"/>
                <counts group_id="E2" subjects_affected="185" subjects_at_risk="1335"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Masahiko Abe, Director Cardiovascular Projects</name_or_title>
      <organization>Department of Clinical Research and Development, Otsuka Pharmaceutical Co., Ltd.</organization>
      <phone>+81-6-6943-7722 ext 2545</phone>
      <email>abems@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

